Becton, Dickinson and Company
BDX Healthcare Medical Instruments & Supplies
In the quarter to June 2026, revenue grew 5.44%, EPS fell 31.5%, free cash flow fell 31.6% and total debt fell 22.9%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for three.
Follow BDX
Becton, Dickinson and Company (BDX) EPS (diluted)
Becton, Dickinson and Company's EPS (diluted) for fiscal 2025 was $5.82, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $3.32. Over the past ten years it has ranged from $0.60 (fiscal 2018) to $6.85 (fiscal 2021); the current reading is higher than 73% of that period. Becton, Dickinson and Company ranks 8th of 49 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $5.82 | (1.85%) |
| FY2024 | $5.93 | 20.04% |
| FY2023 | $4.94 | (15.99%) |
| FY2022 | $5.88 | (14.16%) |
| FY2021 | $6.85 | 152.77% |
| FY2020 | $2.71 | (30.33%) |
| FY2019 | $3.89 | 548.33% |
| FY2018 | $0.60 | (86.96%) |
| FY2017 | $4.60 | 2.45% |
| FY2016 | $4.49 | 34.03% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $1.37 | — |
| Mar 2026 | −$1.11 | — |
| Dec 2025 | $1.34 | (22.09%) |
| Sep 2025 | $1.72 | (14.00%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| RMD ResMed Inc. compare | $10.43 |
| ISRG Intuitive Surgical, Inc. compare | $8.73 |
| SOLV Solventum Corporation compare | $8.18 |
| WST West Pharmaceutical Services, Inc. compare | $7.81 |
| BDX Becton, Dickinson and Company | $3.32 |
| ALC Alcon compare | $1.31 |
| RGEN Repligen Corporation compare | $0.73 |
| BAX Baxter International Inc. compare | −$2.07 |
| MDLN Medline Inc. compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BDX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement